Entrada Therapeutics (NASDAQ:TRDA) was given a new $20.00 price target on by analysts at Guggenheim. They now have a "buy" rating on the stock.
Entrada Therapeutics to Present at Upcoming Investor Conferences [Yahoo! Finance]
Entrada Therapeutics to Present at Upcoming Investor Conferences
Entrada Therapeutics (NASDAQ:TRDA) is now covered by analysts at Oppenheimer Holdings, Inc.. They set an "outperform" rating and a $21.00 price target on the stock.
Entrada Therapeutics Highlights Progress Across its Portfolio of RNA-based Therapeutics for the Treatment of Neuromuscular and Ocular Diseases